Thromboinflammatory biomarkers in obstetric pathophysiology: Predictive insights into placental insufficiency and feto-maternal adverse outcomes

Abstract

Background: Placental insufficiency is a key pathological process underlying major obstetric complications, including pre-eclampsia, fetal growth restriction (FGR), placental abruption, recurrent pregnancy loss, preterm birth and stillbirth. Emerging evidence identifies thromboinflammation—the interplay between coagulation, inflammation, endothelial dysfunction, platelet activation and complement pathways—as a central contributor to these adverse outcomes.

Objective: To critically evaluate the current evidence on thromboinflammatory biomarkers associated with placental insufficiency and adverse feto-maternal outcomes, emphasising their biological relevance, predictive value and clinical applicability.

Methods: A narrative review of literature from PubMed, Scopus, Web of Science, Embase and Google Scholar was conducted. Priority was given to systematic reviews, meta-analyses, prospective studies and international guidelines. Evidence on coagulation, inflammatory, angiogenic, endothelial, complement and emerging molecular biomarkers was synthesised.

Results: Among available biomarkers, the soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio demonstrates the strongest clinical utility for predicting and managing placental dysfunction and pre-eclampsia. Conventional markers, including D-dimer, fibrinogen, platelet indices, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio, provide additional prognostic information, but show variable predictive performance. Emerging biomarkers such as neutrophil extracellular traps, extracellular vesicles, complement activation products, cell-free DNA and circulating microRNAs offer mechanistic insights but remain investigational due to limited standardisation and validation. Multimarker approaches appear superior to individual biomarkers for risk prediction.

Conclusion: Thromboinflammatory biomarkers provide valuable insights into placental dysfunction and adverse pregnancy outcomes. While angiogenic biomarkers currently have the greatest clinical utility, integrated multimarker models may enhance future precision obstetric care. Further large-scale validation studies are required for clinical translation.

Keywords

biomarkers / fetal growth restriction / placental insufficiency / pre-eclampsia / thromboinflammation

References

[1] Miller SL, Huppi PS, Mallard C. The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome. J Physiol. 2016; 594(4): 807-823.

[2] Krishna U, Bhalerao S. Placental insufficiency and fetal growth restriction. J Obstet Gynaecol India. 2011; 61(5): 505-511.

[3] Himoto Y, Fujimoto K, Chigusa Y, et al. Toward clinical implementation of magnetic resonance imaging for placental function. Magn Reson Med Sci. 2025; 24(3): 343-353.

[4] Obeagu EI, Obeagu GU. An update on factors affecting umbilical cord care among mothers: a review. Medicine (Baltimore). 2024; 103(28): e38945.

[5] Yoon HJ. Coagulation abnormalities and bleeding in pregnancy: an anesthesiologist's perspective. Anesth Pain Med (Seoul). 2019; 14(4): 371-379.

[6] Obeagu EI, Obeagu GU. Hematological factors in women with Asherman syndrome and primary infertility: an overview. Medicine (Baltimore). 2025; 104(43): e45562.

[7] Balkaş G, Çelen Ş, Role of inflammatory and coagulation biomarkers in distinguishing placenta accreta from placenta previa and associated hemorrhage. J Clin Med. 2025; 14(11): 3884.

[8] Billoir P, Alexandre K, Duflot T, et al. Investigation of coagulation biomarkers to assess clinical deterioration in SARS-CoV-2 infection. Front Med (Lausanne). 2021; 8: 670694.

[9] Tomkiewicz J, Darmochwał-Kolarz DA. Biomarkers for early prediction and management of preeclampsia: a comprehensive review. Med Sci Monit. 2024; 30: e944104.

[10] Jin PP, Ding N, Dai J, Liu XY, Mao PM. Investigation of the relationship between changes in maternal coagulation profile in the first trimester and the risk of developing preeclampsia. Heliyon. 2023; 9(7): e17983.

[11] Filip C, Matasariu DR, Ursache A, et al. Exploring biomarkers to predict thrombogenic risk in pregnancy. J Clin Med. 2025; 14(3): 932.

[12] Gladstone RA, Snelgrove JW, McLaughlin K, et al. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt1): powerful new tools to guide obstetric and medical care in pregnancy. Obstet Med. 2025; 18(3): 143-149.

[13] Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome. Hypertension. 2020; 75(4): 918-926.

[14] Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016; 27(2): 89-94.

[15] Samfireag M, Potre C, Potre O, Tudor R, Hoinoiu T, Anghel A. Approach to thrombophilia in pregnancy—a narrative review. Medicina (Kaunas). 2022; 58(5): 692.

[16] Guerby P, Tasta O, Swiader A, et al. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biol. 2021; 40: 101861.

[17] Vornic I, Buciu V, Furau CG, et al, et al. Oxidative stress and placental pathogenesis: a contemporary overview of potential biomarkers and emerging therapeutics. Int J Mol Sci. 2024; 25(22): 12195.

[18] Palomo M, Moreno-Castaño AB, Salas MQ, et al. Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications. Front Med (Lausanne). 2023; 10: 1285898.

[19] Chen Q, Li D, Zheng Y, et al. The maternal-fetal interface fibrin deposition and expression of FGL2 in the placenta of preeclampsia and fetal growth restriction. Int J Gynecol Pathol. 2025; 44(5): 436-444.

[20] Mastrolia SA, Mazor M, Loverro G, Klaitman V, Erez O. Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes. PeerJ. 2014; 2: e653.

[21] Yatsenko T, Us I, Korolova D, et al. Placental dysfunction is associated with dysregulated fibrinolytic system activation. Int J Mol Sci. 2025; 26(19): 9339.

[22] Gorio C, Molinari AC, Martini T, et al. Hemostasis laboratory diagnostics in newborns. J Clin Med. 2025; 14(14): 5068.

[23] Greer IA, Aharon A, Brenner B, Gris JC. Coagulation and placenta-mediated complications. Rambam Maimonides Med J. 2014; 5(4): e0034.

[24] Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015; 29(1): 17-24.

[25] Li S, Qian Y, Pei Y, Wu K, Lu S. Coagulation and fibrinolysis biomarkers as potential indicators for the diagnosis and classification of ovarian hyperstimulation syndrome. Front Med (Lausanne). 2021; 8: 720342.

[26] Bardan CR, Ioniță I, Iordache M, et al. Epigenetic biomarkers in thrombophilia-related pregnancy complications: mechanisms, diagnostic potential, and therapeutic implications: a narrative review. Int J Mol Sci. 2024; 25(24): 13634.

[27] Belali TM. An increased plasma D-dimer levels during different stages of normal and complicated pregnancies among women in Bisha, Saudi Arabia. J Blood Med. 2025; 16: 349-358.

[28] Hale SA, Sobel B, Benvenuto A, Schonberg A, Badger GJ, Bernstein IM. Coagulation and fibrinolytic system protein profiles in women with normal pregnancies and pregnancies complicated by hypertension. Pregnancy Hypertens. 2012; 2(2): 152-157.

[29] Wang L, Zhong J, Xiao D, Huang W, Zheng Z, Jiang Y. Thrombomodulin (TM), thrombin–antithrombin complex (TAT), plasmin-α2-plasmininhibitor complex (PIC), and tissue plasminogen activator-inhibitor complex (t-PAIC) assessment of fibrinolytic activity in postpartum hemorrhage: a retrospective comparative cohort study. Ann Transl Med. 2022; 10(23): 1273.

[30] Yoshihisa A, Sato Y, Kimishima Y, et al. Soluble fibrin monomer complex is associated with cardio- and cerebrovascular events in patients with heart failure. Int J Cardiol Heart Vasc. 2020; 32: 100697.

[31] Kobayashi H, Matsubara S, Yoshimoto C, Shigetomi H, Imanaka S. Tissue factor pathway inhibitors as potential targets for understanding the pathophysiology of preeclampsia. Biomedicines. 2023; 11(5): 1237.

[32] Hong J, Kumar S. Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction. Clin Sci (Lond). 2023; 137(8): 579-595.

[33] Ernst LM, Freedman AA, Odom-Konja RM, et al. Associations of serum inflammatory biomarkers during pregnancy with placental pathology and placental gene expression at delivery. Am J Reprod Immunol. 2025; 93(4): e70062.

[34] Chiang YT, Seow KM, Chen KH. The pathophysiological, genetic, and hormonal changes in preeclampsia: a systematic review of the molecular mechanisms. Int J Mol Sci. 2024; 25(8): 4532.

[35] Cristodoro M, Messa M, Tossetta G, et al. First trimester placental biomarkers for pregnancy outcomes. Int J Mol Sci. 2024; 25(11): 6136.

[36] Cuffe JSM, Holland O, Salomon C, Rice GE, Perkins AV. Review: placental derived biomarkers of pregnancy disorders. Placenta. 2017; 54: 104-110.

[37] Dröge LA, Perschel FH, Stütz N, et al. Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study. Hypertension. 2021; 77(2): 461-471.

[38] Gigase FAJ, Boekhorst MMGBM, Suleri A, et al. Maternal immune activation during pregnancy and obstetric outcomes: a population-based cohort study. BJOG. 2025; 132(9): 1307-1318.

[39] Guo X, Tao W, Zhao Q, et al. Correlation between immune-inflammatory biomarkers during pregnancy and postpartum and adverse outcomes of preeclampsia: a longitudinal retrospective analysis. J Inflamm Res. 2025; 18: 12713-12723.

[40] Kurmanova A, Nurmakova A, Salimbayeva D, et al. Systemic and local immunological markers in preeclampsia. Diagnostics (Basel). 2025; 15(13): 1644.

[41] Moyle KA, Branch DW, Peterson LK, et al. Association between novel antiphospholipid antibodies and adverse pregnancy outcomes. Obstet Gynecol. 2025; 145(1): 55-64.

[42] Nan MN, García-Osuna Á, Mora J, et al. Impact of angiogenic and cardiovascular biomarkers for prediction of placental dysfunction in the first trimester of pregnancy. Biomedicines. 2023; 11(5): 1327.

[43] Parry S, Carper BA, Grobman WA, et al. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients. Am J Obstet Gynecol. 2022; 227(3): 497.e1-497.e13.

[44] Reddy M, Palmer K, Rolnik DL, Wallace EM, Mol BW, Da Silva Costa F. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2022; 59(5): 596-605.

[45] Sovio U, Gaccioli F, Cook E, Charnock-Jones DS, Smith GCS. Association between adverse pregnancy outcome and placental biomarkers in the first trimester: a prospective cohort study. BJOG. 2024; 131(6): 823-831.

[46] Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7): 672-83.

[47] Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019; 124(7): 1094-1112.

[48] Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021; 398(10297): 341-354.

[49] Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308(5728): 1592-4.

[50] Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol. 2018; 218(2S): S745-S761.

[51] Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017; 377(7): 613-622.

[52] Mitranovici M-I, Chiorean DM, Moraru R, et al. Understanding the pathophysiology of preeclampsia: exploring the role of antiphospholipid antibodies and future directions. J Clin Med. 2024; 13(9): 2668.

[53] Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019; 145(Suppl 1): 1-33.

[54] Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018; 13: 291-310.

[55] National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: Diagnosis and management (NG133). NICE; 2019. https://www.nice.org.uk/guidance/ng133

[56] Royal College of Obstetricians and Gynaecologists (RCOG). Green-top guideline No. 10A: The management of severe pre-eclampsia/eclampsia. ECOG; 2019. https://www.rcog.org.uk

[57] American College of Obstetricians and Gynecologists (ACOG). Gestational hypertension and preeclampsia: ACOG practice bulletin No. 222. Obstet Gynecol. 2020; 135(6): e237-e260.

[58] Liu F, Su Y, Liu X, et al. Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders. Front Pharmacol. 2025; 16: 1537934.

[59] Liang L, Chen Y, Wu C, et al. MicroRNAs: key regulators of the trophoblast function in pregnancy disorders. J Assist Reprod Genet. 2023; 40(1): 3-17.

[60] Jaszczuk I, Winkler I, Koczkodaj D, Skrzypczak M, Filip A. The role of cluster C19MC in pre-eclampsia development. Int J Mol Sci. 2022; 23(22): 13836.

[61] Abdeldaem Mohamed RH, Ahmed Ali Alfaki NM, Belal RE, et al. Biomarkers of inflammation and their association with the severity and onset of preeclampsia: a Systematic review. Cureus. 2025; 17(7): e87734.

[62] Wishlade T, Wetzler S, Aiken CE. Biomarkers predicting adverse pregnancy outcomes in women living with obesity: a systematic review and meta-analysis. AJOG Glob Rep. 2025; 5(3): 100527.

[63] Garcia-Larragoiti N, Cano-Mendez A, Jimenez-Vega Y, et al. Inflammatory and Prothrombotic biomarkers contribute to the persistence of sequelae in recovered COVID-19 patients. Int J Mol Sci. 2023; 24(24): 17468.

[64] Rus H, Cudrici C, Niculescu F. The role of the complement system in innate immunity. Immunol Res. 2005; 33(2): 103-112.

[65] Varela JC, Tomlinson S. Complement: an overview for the clinician. Hematol Oncol Clin North Am. 2015; 29(3): 409-427.

[66] Burwick RM, Java A, Regal JF. The role of complement in normal pregnancy and preeclampsia. Front Immunol. 2025; 16: 1643896.

[67] Pierik E, Prins JR, van Goor H, et al. Dysregulation of complement activation and placental dysfunction: a potential target to treat preeclampsia? Front Immunol. 2020; 10: 3098.

[68] Burwick RM, Java A, Regal JF. The role of complement in normal pregnancy and preeclampsia. Front Immunol. 2025; 16: 1643896.

[69] Inthavong S, Jatavan P, Tongsong T. Predictive utility of biochemical markers for the diagnosis and prognosis of gestational diabetes mellitus. Int J Mol Sci. 2024; 25(21): 11666.

[70] Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003; 112(11): 1644-1654.

[71] Ibrahim RB, Almamoun R, Sartain SE, Devaraj S. Soluble C5b-9 (sC5b-9) in Pediatrics-A clinical assessment. J Clin Lab Anal. 2025; 39(23): e70122.

[72] Ji C, Xu H, Liu Y, Ji G, Li H, Weng Z. Atypical hemolytic uremic syndrome after post-abortion infection: case report and literature review. Int J Womens Health. 2025; 17: 5689-5694.

[73] Velickovic I, Dalloul M, Wong KA, et al. Complement factor B activation in patients with preeclampsia. J Reprod Immunol. 2015; 109: 94-100.

[74] Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol 2019;10: 449.

[75] Tagara S, Valsami S, Gavriilaki E, et al. Activated complement system's impact in antiphospholipid syndrome thrombosis: From pathophysiology to treatment. J Clin Med. 2025; 14(18): 6672.

[76] Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. interactions between coagulation and complement–their role in inflammation. Semin Immunopathol. 2012; 34(1): 151-165.

Rights & permissions

2026 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.